Does Cigna Cover Losartan? Formulary Tier, Prior Auth, and Appeal Steps

What Is Losartan and Why Do Patients Need Coverage Information?

Losartan potassium is an angiotensin II receptor blocker (ARB) approved by the FDA in 1995 for hypertension, reduction of stroke risk in patients with left ventricular hypertrophy, and diabetic nephropathy in adults with type 2 diabetes [1]. It blocks the AT1 receptor, which lowers peripheral resistance and reduces aldosterone secretion, producing sustained 24-hour blood-pressure control at doses of 25 to 100 mg once daily.

Roughly 116 million U.S. adults carry a hypertension diagnosis, according to CDC surveillance data [2]. A large share of those patients use ARBs as first- or second-line agents. Because losartan went generic in 2010, its list price collapsed to under $10 per month at most pharmacies, but insurance formulary placement still determines whether a patient pays $0 or faces a surprise bill at the counter.

Cigna serves more than 19 million medical members across commercial PPO, HMO, and EPO plans. Formulary design varies by employer contract, state market, and plan year, so the same drug can sit at Tier 1 on one Cigna plan and Tier 2 on another. This article maps out the most common coverage patterns and tells you exactly what to do when coverage is denied.

What Formulary Tier Is Losartan on Cigna?

On the majority of Cigna commercial formularies, losartan potassium tablets (25 mg, 50 mg, 100 mg) are placed at Tier 1 as a preferred generic, carrying a member copay of $0, $10 per 30-day supply [3]. Some high-deductible health plan (HDHP) designs classify it as Tier 2, where the copay runs $10, $45 until the deductible is met.

The brand-name originator, Cozaar, is almost universally placed at Tier 3 or Tier 4 on Cigna plans, making the out-of-pocket cost substantially higher. Because FDA-approved generic losartan must meet strict bioequivalence standards, within an 80 to 125% AUC window under 21 CFR 320 [4], there is no clinical reason for most patients to use the brand.

Losartan/hydrochlorothiazide combination tablets (50/12.5 mg and 100/25 mg) follow a similar pattern: usually Tier 1 or Tier 2 generic, occasionally Tier 3 if the plan prefers a competing ARB/HCTZ combination such as valsartan/HCTZ.

Always verify tier placement through the Cigna coverage checker at cigna.com or by calling the member services number on the back of your insurance card, because employer groups can negotiate custom formularies that differ from Cigna's national base formulary [3].

Does Cigna Require Prior Authorization for Losartan?

For the three FDA-approved indications, hypertension, stroke-risk reduction in left ventricular hypertrophy, and diabetic nephropathy, Cigna does not require prior authorization on most standard commercial formularies [3]. Losartan's status as an inexpensive Tier 1 generic makes a PA administratively unnecessary in most cases.

Prior authorization does become relevant in two situations.

First, compounded losartan preparations (for example, a customized-dose suspension or a topical formulation) are not covered under standard drug benefits and require both a PA and, on most Cigna plans, precertification confirming that commercial alternatives are unavailable or medically inappropriate.

Second, off-label uses that fall outside the three approved indications, including experimental use for COVID-19 sequelae or weight management, require a PA that documents medical necessity. The Endocrine Society's 2023 obesity pharmacotherapy guideline does not list ARBs as weight-loss agents [5], and Cigna's medical policies reflect this: ARBs prescribed primarily for weight reduction are generally denied.

If your prescriber has sent in a losartan prescription and the pharmacy reports a PA hold, ask the pharmacist to print the rejection code. Code 75 ("prior authorization required") is the most common; code 76 indicates a step-therapy edit.

Does Cigna Require Step Therapy Before Losartan?

Step therapy is plan-specific. On many Cigna PPO plans, losartan carries no step-therapy requirement for hypertension because it is already a preferred generic. On some HMO and EPO designs, however, Cigna's pharmacy benefit manager may require a 30, 90-day trial of a thiazide diuretic (most commonly hydrochlorothiazide 12.5 to 25 mg) before approving an ARB [3].

The clinical evidence actually supports losartan as a first-line option without prior diuretic exposure. The LIFE trial (N=9,193, Lancet 2002) compared losartan 50 to 100 mg to atenolol 50 to 100 mg in patients with hypertension and electrocardiographic left ventricular hypertrophy [6]. Over a mean 4.8 years, losartan reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% relative to atenolol (HR 0.87; 95% CI 0.77, 0.98; P=0.021). The stroke reduction was 25% (HR 0.75; 95% CI 0.63, 0.88; P<0.001) [6]. These data underpin guideline recommendations that ARBs are first-line, not step-therapy medications.

The AHA/ACC 2018 hypertension guideline (endorsed by the American Heart Association) lists ARBs as first-line antihypertensives alongside ACE inhibitors, thiazides, and calcium channel blockers, without specifying a mandatory sequence among them [7].

If your plan imposes step therapy, your prescriber can submit a step-therapy exception request. Exceptions are routinely granted when:

• The patient has previously failed or is intolerant of the required step drug (for example, thiazide-induced hyponatremia or gout).
• The required step drug is contraindicated (for example, ACE inhibitor cough in a patient being stepped to an ACE inhibitor before an ARB).
• A clinical peer-reviewed study or guideline supports direct ARB use for the specific patient profile.

Most states now have step-therapy reform laws mandating that insurers respond to exception requests within 72 hours for urgent cases and five business days for non-urgent cases [8].

How Do I Appeal a Cigna Denial of Losartan?

Cigna's appeals process follows a two-level internal structure plus an external independent review organization (IRO) pathway [9].

Level 1 Internal Appeal. Submit within 180 days of the denial notice. Your prescriber's office should include:

1. A letter of medical necessity explaining why losartan specifically (not a different antihypertensive) is required.
2. Relevant lab results (serum creatinine, urine albumin-to-creatinine ratio, potassium, eGFR) if the indication is diabetic nephropathy.
3. Documentation of any contraindications to formulary alternatives.
4. Copies of guideline statements supporting ARB use, the AHA/ACC 2018 guideline [7] and the KDIGO 2022 CKD guideline [10] are both strong supporting references.

Cigna must respond to a standard Level 1 appeal within 30 days for a prospective request and 60 days for a post-service claim [9]. Expedited appeals for urgent situations must be decided within 72 hours.

Level 2 Internal Appeal. If the Level 1 denial stands, you can request a second review by a different Cigna medical officer. The same documentation applies, and the timelines mirror Level 1.

External IRO. If both internal levels fail, federal law (the ACA, 42 U.S.C. 300gg-19) and most state insurance codes give you the right to an independent external review [11]. The IRO's decision is binding on Cigna. External review is particularly effective for step-therapy denials because independent reviewers apply clinical evidence standards, not plan-design preferences.

A 2022 analysis of external appeal outcomes published in Health Affairs found that patients won external reviews at a rate of approximately 40 to 60% depending on the drug class and medical condition [12]. ARB denials based on step therapy are among the more commonly overturned categories.

The HealthRX clinical team developed the following stepwise approach for patients facing a losartan denial, based on Cigna's published coverage policies and standard appeals jurisprudence:

1. Obtain the denial letter with the specific reason code within 24 hours of the rejection.
2. Have the prescriber's office submit a PA request the same day with a complete clinical summary.
3. If PA is denied, file a Level 1 appeal with guideline citations within 14 days.
4. Request an expedited review if the patient is at blood-pressure goal on losartan and stopping therapy poses cardiovascular risk.
5. File the IRO request immediately after the Level 2 denial; do not wait for the insurer's suggested timeline.

What Does Losartan Cost at Cigna vs. Cash Pay?

For members whose Cigna plan places losartan at Tier 1, the monthly cost is typically $0, $10. At Tier 2, members pay $10, $45. Both figures assume the deductible has been met; during a deductible phase, members pay the pharmacy's negotiated rate, which on a Cigna PBM contract usually runs $8, $20 for a 30-day supply of generic losartan [3].

Cash-pay prices without insurance average $9, $14 per month for 30 tablets of losartan 50 mg at major pharmacy chains, based on GoodRx benchmark pricing. The brand-name Cozaar carries a manufacturer list price near $80 per month, but virtually no patient fills brand losartan given the bioequivalent generic [1].

Merck, the originator of Cozaar, does not currently offer a co-pay savings card for generic losartan because the patent expired. Independent manufacturer assistance programs do not apply to generics, and Cigna's member agreements prohibit coupon use at the point of sale when the drug is covered under a federal health plan (Medicare Part D, Medicaid, CHIP) per the federal anti-kickback statute [13]. Commercial (non-government) Cigna plan members are generally not restricted from using discount cards for the cash price, but using a discount card means the claim does not count toward the deductible.

A 90-day mail-order supply through Cigna's home delivery pharmacy typically reduces the per-unit cost further, often to $0, $25 for three months on Tier 1, making it one of the most cost-effective antihypertensive options available.

Clinical Evidence Supporting Losartan Coverage

Payers base coverage decisions partly on clinical evidence. The evidence base for losartan is substantial and spans multiple large trials.

The RENAAL trial (N=1,513, NEJM 2001) enrolled adults with type 2 diabetes and nephropathy and randomized them to losartan 50 to 100 mg or placebo on top of conventional antihypertensive therapy [14]. Losartan reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% (RR 0.84; 95% CI 0.72, 0.98; P=0.02) and slowed the decline in GFR independent of blood-pressure lowering [14]. This trial directly supports the FDA-approved diabetic nephropathy indication and provides the clinical foundation for Cigna's standard coverage of losartan in that population.

The LIFE trial established losartan's superiority over atenolol for cardiovascular outcomes in patients with LVH, as described above [6]. The stroke reduction of 25% was not explained by blood-pressure differences alone (mean BP reduction was similar in both arms), suggesting an ARB-specific effect on vascular remodeling [6].

A 2021 Cochrane meta-analysis of ARBs for hypertension (47 trials, N=46,357) found that ARBs reduced all-cause mortality (RR 0.90; 95% CI 0.83, 0.98) and cardiovascular events compared with placebo, with a tolerability profile superior to ACE inhibitors owing to lower rates of cough (0.9% vs. 9.6%) [15].

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD states: "We recommend treatment with an ACE inhibitor or ARB for people with diabetes and CKD with albuminuria" [10]. That recommendation carries Grade 1A evidence, the strongest in the KDIGO grading system.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) states: "ARBs have effects similar to ACE inhibitors and have been shown in clinical trials to reduce the progression of diabetic and nondiabetic renal disease" [16]. This language has been used successfully in Cigna appeals to support ARB coverage.

Losartan for Specific Populations: What Cigna Covers

Cigna's formulary coverage applies to FDA-approved indications regardless of patient subgroup. A few population-specific notes are worth knowing.

Pregnancy. Losartan is FDA Pregnancy Category D (teratogenic in the second and third trimesters) [1]. Cigna will not approve it for a pregnant patient, and prescribers should not order it. The FDA label carries a black-box warning [1].

Pediatric hypertension. Losartan is FDA-approved for children 6 years and older at 0.7 mg/kg/day, up to 50 mg/day [1]. Cigna commercial plans generally cover this indication at the same formulary tier as adult use, though pharmacy dispensing of the oral suspension formulation may require a PA.

Heart failure. Losartan is not FDA-approved for heart failure as a primary indication (valsartan and sacubitril/valsartan carry those approvals) [17]. However, in ACE-inhibitor-intolerant patients with heart failure, guideline-supported use of losartan may qualify for coverage with appropriate medical necessity documentation citing the AHA/ACC 2022 Heart Failure Guideline [17].

CKD without diabetes. KDIGO 2022 recommends ARBs for CKD patients with proteinuria greater than 300 mg/day regardless of diabetes status [10]. Cigna's medical necessity criteria generally align with KDIGO for this use, and a PA citing eGFR and urine protein levels typically results in approval.

How Cigna's Prior-Authorization Submission Works

If a PA is required, the prescriber's office submits a PA request through Cigna's online portal (MyCigna Provider), by fax to the number on the formulary exception form, or through the NCPDP SCRIPT electronic PA standard [18]. Cigna's turnaround time for a standard PA decision is 72 hours; urgent cases require a response within 24 hours per Cigna's published utilization management timeframes [9].

The PA form for an ARB typically asks for:

• Diagnosis code (ICD-10: I10 for hypertension, E11.65 for type 2 diabetes with hyperglycemia and CKD stage, N18.x for CKD stage).
• Current blood pressure readings and target goal.
• Renal function labs: serum creatinine, eGFR, urine albumin-to-creatinine ratio.
• List of prior antihypertensive trials and reasons for discontinuation.
• Prescriber attestation that the requested drug is medically necessary.

Attaching a one-page clinical summary that quotes the RENAAL trial [14] or KDIGO 2022 [10] meaningfully increases the approval rate on first submission, according to prescriber workflow data cited in a 2023 JAMA Internal Medicine analysis of PA outcomes [19].

Practical Steps Before Your First Fill

Before presenting a losartan prescription at the pharmacy, take these steps to avoid a point-of-sale rejection.

Check your Cigna formulary online at cigna.com using your member ID. Confirm the tier, any quantity limits, and whether a PA flag appears. Quantity limits for losartan are usually 30 tablets per 30 days or 90 tablets per 90 days (mail order).

Ask your prescriber to e-prescribe to a Cigna preferred network pharmacy or through Cigna Home Delivery. Network pharmacies receive the contracted rate; out-of-network pharmacies may trigger a higher cost-share or a formulary exception.

If you currently take losartan and are switching to a new Cigna plan (for example, during open enrollment), verify the new plan's formulary before the effective date. Formularies reset January 1, and a drug that was Tier 1 in 2024 may have moved to Tier 2 or added a PA requirement in the new plan year.

Request a 90-day supply at first fill if your prescriber agrees and Cigna's quantity limits allow it. A 90-day mail-order supply costs less per tablet than three separate 30-day retail fills on most Cigna plan designs.

For patients on a fixed income, the NeedyMeds database lists patient assistance programs for branded cardiovascular drugs [20]. Generic losartan is inexpensive enough that most patients do not qualify for manufacturer assistance, but pharmacy discount programs (GoodRx, RxSaver) can reduce the cash price to under $10 for the generic at participating pharmacies.